India  

No approval for Covaxin, expert panel seeks more data from Bharat Biotech

IndiaTimes Friday, 1 January 2021
The Subject Expert Committee of the Central Drug Standard Control Organisation on Friday has held that the data provided by Bharat Biotech for its coronavirus vaccine 'Covaxin' is not sufficient for grant of emergency use approval and has asked for more information, top sources said.
0
shares
ShareTweetSavePostSend
 
Video Credit: ANI - Published
News video: COVAXIN has shown less than 10% adverse reactions: Bharat Biotech MD

COVAXIN has shown less than 10% adverse reactions: Bharat Biotech MD 01:42

While addressing a press conference via video conferencing in Hyderabad on January 04, the Chairman and Managing Director (MD) of Bharat Biotech International Limited, Dr Krishna M Ella said, "COVAXIN has shown less than 10% adverse reactions, while others have 60-70% adverse reactions. AstraZeneca...

You Might Like


💡 newsR Knowledge: Other News Mentions

Covaxin Covaxin Vaccine against COVID-19

CDSCO expert panel recommends nod to study on mixing doses of Covaxin, Covishield

An expert panel of India's central drug authority on Thursday recommended granting permission to the Christian Medical College (CMC) in Vellore for conducting a..
IndiaTimes

Brazil's Anvisa provisionally suspends authorisation for exceptional import of 4 million Covaxin doses

After closing the emergency use authorisation (EUA) and Phase-3 clinical trials requests for Bharat Biotech’s Covaxin, Brazil’s health regulator Anvisa..
IndiaTimes

After suspending Covaxin clinical trials, Brazil closes EUA request

After suspending the clinical trials of Covaxin following the termination of Bharat Biotech's MoU with its Brazilian partner Precisa Medicamentos, Brazil’s..
IndiaTimes

COVID-19 vaccine for children likely by September: AIIMS Chief

In view of a probable third wave of the pandemic, vaccination trials on children have been underway in India with Covaxin and Zydus Cadila's ZyCov-D.
DNA

Bharat Biotech Bharat Biotech Indian biotechnology company and vaccine manufacturer

Bharat Biotech commits to supply 500 million doses of Covaxin to Centre for immunisation programme

Bharat Biotech on Friday said it has committed to supply over 500 million doses of its COVID-19 vaccine Covaxin to the Centre under the countrywide immunisation..
IndiaTimes

Related videos from verified sources

TN Health Min takes Bharat Biotech's Covaxin shot in Chennai [Video]

TN Health Min takes Bharat Biotech's Covaxin shot in Chennai

The Health and Family Welfare Minister of Tamil Nadu, Dr C Vijayabaskar took Bharat Biotech's Covaxin shot. He took the shot in Chennai on morning of January 22. Dr C Vijayabaskar requested all to get..

Credit: ANI     Duration: 01:28Published
No Walled Gardens In CTV’s Last Mile: LiveRamp’s Jay Prasad [Video]

No Walled Gardens In CTV’s Last Mile: LiveRamp’s Jay Prasad

Connected TV has come a long way - but it still has a little way to go to fully realize the dreams of efficient, data-driven advertising that reaches individual homes. EMarketer forecasts US connected..

Credit: BeetTV - Affiliate     Duration: 09:03Published
Covaxin: Do not inject if you have these conditions | Oneindia News [Video]

Covaxin: Do not inject if you have these conditions | Oneindia News

Covaxin maker Bharat Biotech has issued a fact sheet which details which categories of people should not be administered with the vaccine or which groups should take the vaccine with caution. Watch the..

Credit: Oneindia     Duration: 01:08Published

Related news from verified sources

Plea in Bombay HC on safety of Covaxin, Bharat Biotech to pay compensation for any side effect

Bharat Biotech, has received a government purchase order for the supply of 55 lakh doses of Covaxin.
DNA Also reported by •IndiaTimesMid-Day

Centre issues Letter of Comfort to Bharat Biotech for 45 lakh doses of Covaxin

Bharat Biotech has secured a fresh Letter of Comfort from the Centre for another 45 lakh doses of its COVID-19 vaccine, Covaxin, sources said. ​​Out of the...
IndiaTimes Also reported by •Mid-Day

Compensation if Covaxin causes serious adverse effect

Beneficiaries who receive Covaxin, a Bharat Biotech product, will be paid a compensation if they suffer a serious adverse event that is proven to be causally...
IndiaTimes